An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in CAH at ENDO 2026 On June 14, Crinetics Pharmaceuticals, Inc. presented data from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral...
Author: Mark Newman
Meet Incoming Endocrine Society President Nanette Santoro, MD
Nanette Santoro, MD, knew she wanted to be a doctor at age 16, feeling like it was the best way to help people, something that would be good for mankind. The Endocrine Society is pleased to welcome Santoro, of the University of Colorado School of Medicine in Aurora, Colo., as its 2026 – 2027 president....Endocrine Society Guideline Addresses Different Subgroups of Central Precocious Puberty
Some subgroups of children with precocious puberty — such as older girls with slowly progressing puberty—may not need the same level of testing or treatment, according to a new Endocrine Society Clinical Practice Guideline released today. “Children who start puberty earlier than usual should be carefully evaluated so they receive the right care at the right time—without...
Take Me Back to Chicago: ENDO 2026 Returns to the Windy City
Discover the latest advances in hormone research and clinical endocrinology at ENDO 2026. This year’s conference, taking place in Chicago, Ill., June 13-16, 2026, is designed to enhance your knowledge and skills in endocrinology with a mix of programs for both the clinician and researcher. With an extensive program covering a broad array of topics,...
To T or Not To T: Should We Treat Low Testosterone in Men with Obesity?
Whether to treat low testosterone in men with obesity will be the topic of “Low Testosterone in Obesity: Should We Treat or Not?” a debate session at ENDO 2026 that is sure to be somewhat vigorous as two experts in the field take sides in a session moderated by Endocrine Society Past-President Stephen Hammes, MD,...Endocrine Society and Keystone Symposia Announce Series of Joint Meetings
The Endocrine Society and Keystone Symposia are partnering to hold a series of joint translation scientific meetings that connect foundational (or basic) science with clinical practice across oncology, cardiometabolism, and diabetes with the aim of supporting a full bench-to-bedside and back research cycle. Keystone Symposia contributes deep connections to basic scientists and a robust infrastructure...
How the Endocrine Society’s Corporate Liaison Board fosters collaboration, fuels innovation, and advances patient care The Endocrine Society (the Society) strives to foster an interdisciplinary community of those practicing, researching, and innovating in endocrinology. Industry is an important site of innovation in endocrinology, and the Society’s Corporate Liaison Board (CLB) plays a pivotal role in...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo...
